<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="447">
  <stage>Registered</stage>
  <submitdate>30/04/2004</submitdate>
  <approvaldate>30/04/2004</approvaldate>
  <nctid>NCT00082186</nctid>
  <trial_identification>
    <studytitle>The Effect of Tracleer® on Male Fertility</studytitle>
    <scientifictitle>TRACLEER® (Bosentan) Pulmonary Arterial Hypertension A Multicenter, Open-label, Single-arm Safety Study to Investigate the Effects of Chronic TRACLEER® Treatment on Testicular Function in Male Patients With Pulmonary Arterial Hypertension</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AC-052-402</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hypertension, Pulmonary</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - bosentan

Experimental: 1 - Oral bosentan tablets


Treatment: drugs: bosentan
Oral bosentan tablets 62.5 mg twice daly for 4 weeks, then 125 mg twice daily for 20 weeks.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of patients with a mean decrease in sperm concentration to 7.5 x 10[6]/mL or below, without a single sperm concentration = 20 x 10[6]/mL, at 3 or 6 months. This proportion is considered of clinical relevance if greater than 30%.</outcome>
      <timepoint>From baseline to end of study.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Semen volume, sperm motility and sperm morphology change</outcome>
      <timepoint>From baseline to 3 &amp; 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male patients age 18-65 years.

          -  Bosentan-naïve.

          -  PPH, WHO functional class III/IV, in need of TRACLEER

          -  Patients pulmonary arterial hypertension (PAH) secondary to congenital heart disease.

          -  Written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Female

          -  Patients with PAH secondary to connective tissue vascular diseases or HIV.

          -  Patients who have undergone a vasectomy.

          -  Patients with an average baseline sperm concentration &lt; 15 x 10[6]/mL, or any sample
             with a sperm concentration &lt;= 7.5 x 10[6]/mL.

          -  Patients with an average baseline sperm motility &lt;20% or normal sperm morphology &lt;5%.

          -  Body weight &lt; 50 kg.

          -  Hypotension, defined as systolic blood pressure less than 85 mm Hg.

          -  AST and/or ALT plasma levels greater than 3 times ULN.

          -  Hypersensitivity to bosentan or any of the components of the formulation.

          -  Treatment with glyburide, cyclosporine A or tacrolimus at inclusion or planned during
             the study.

          -  Treatment with hormone suppressive agents, including androgens, estrogens, anabolic
             steroids or glucocorticoids within the past 6 months or planned during the study.

          -  Current treatment less than 3 months prior to inclusion or planned treatment with
             prostacyclin or prostacyclin analogues (e.g., Flolanâ or Remodulin).

          -  Patients who received an investigational drug in the month preceding the study start
             or who are due to be treated with another investigational drug during the study
             period.

          -  Known drug or alcohol dependence or any other factors that will interfere with conduct
             of the study.

          -  Any illness other than PPH that will reduce life expectancy to less than 6 months.

          -  Active cancer.

          -  Prior treatment with an anti-neoplastic agent or ionizing radiation.

          -  Hot tub/Jacuzzi use.

          -  Uncontrolled diseases including diabetes, liver or kidney disease.

          -  Patients receiving spironolactone (aldactone) less than 3 months prior to inclusion or
             dose &gt;25 mg/day at baseline or anytime during the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>22</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2007</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>St. Vincent's Hospital - Darlinghurst</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>Sao Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Actelion</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of the study is to evaluate the effects of chronic TRACLEER® treatment on
      testicular function via semen analysis in male patients with primary pulmonary arterial
      hypertension (PAH).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00082186</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrea Lauer, Ph.D.</name>
      <address>Actelion Pharmaceuticals US, Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>